In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Exact Sciences nets $634mm through upsized public notes offering

Executive Summary

Exact Sciences Corp. (molecular diagnostics for early cancer detection) netted $634mm through a public offering of $650mm principal amount of 0.375% senior notes due 2027. (The offering was upsized from $600mm.) The notes convert to common at a rate of 8.9554 shares per $1k principal amount, or $111.6645 per share. The company's stock averaged $89.76 at the time of the sale.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Laboratory Testing Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO

Related Companies